SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

GEO Group is trending as analysts have updated target prices, sparking debate about the company's value and future. Community discussion also includes moral considerations regarding private incarceration and the impact of immigration policies on GEO's business. Some traders are eyeing potential stock buybacks and increased government contracts as possible catalysts.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation that the President may soon sign an executive order regarding marijuana reclassification, potentially as early as Monday, driving excitement among cannabis investors. Community discussions revolve around the potential impact on the sector, particularly regarding tax burdens and access to financial services. Traders are closely watching for a short squeeze and are debating whether to hold through the weekend, anticipating significant after-hours movement.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is trending downwards as investors express concerns about profitability, leadership, and potential regulatory challenges like social media bans for teens in some regions. Community members are debating the company's future prospects, with some highlighting potential in AI and new specs releases while others cite worries about dilution and poor performance relative to the broader market. Discussions also include speculation about a possible acquisition, although negative sentiment appears dominant amid the stock's recent price action.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

Motorola Solutions ($MSI) is trending amid discussions about its oversold conditions and potential for a bullish reversal, with some noting a large dark pool print potentially signaling a bottom. The community is also discussing recent acquisitions and potential benefits from a US-China trade deal, alongside technical analysis pointing to positive divergences. Despite some concerns, many view the company as having strong fundamentals and no competition in its sector.

ARB IOT Group Ltd. is a holding company that engages in the provision of solutions for the integration of IoT systems and devices. It operates through the Internet of Things and Investment Holding and Others segments. The company was founded on March 1, 2022 and is headquartered in Singapore.

ARB IOT Group Ltd

ARBB is trending due to renewed interest in its low float and potential for a short squeeze, with the community actively discussing a possible breakout above a key resistance level. Traders are pointing to a previous AI server deal and the stock's potential to repeat past parabolic runs. The stock's tight share structure is fueling speculation of significant upward movement.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as the stock experiences volatility and a downward trend, sparking debate about its valuation and future prospects. The community is focused on an at-the-market equity offering and its potential impact on stock dilution, as well as contrasting opinions on the company's long-term viability in the small modular reactor (SMR) and AI-driven energy sectors.

Aurora Cannabis, Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products. It operates through the Cannabis and Plant Propagation segments. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Edmonton, Canada.

Aurora Cannabis Inc

Aurora Cannabis is trending as the broader cannabis sector reacts to reports that President Trump may loosen federal restrictions on marijuana. Community members are discussing the potential impact of reclassification on the industry, potential catalysts and the future outlook for cannabis stocks. Some traders are also noting ACB's lower float and potential for a short squeeze.

Argo Blockchain Plc operates as a blockchain technology company focused on large-scale mining of Bitcoin and other cryptocurrencies. It mines using purpose-built computers to solve cryptographic algorithms in the blockchain in exchange for rewards and fees denominated in the native token of that blockchain network. The company was founded in 2017 and is headquartered in London, the United Kingdom.

Argo Blockchain Plc - ADR

Argo Blockchain Plc

ARBK is trending due to a mix of factors, including a recent reverse stock split and London delisting, sparking volatility. The community is debating the impact of potential dilution and whether a squeeze or rebound is likely. Meanwhile, some traders are shifting focus to other low-float stocks, with a few mentioning ARBK's potential correlation with Bitcoin's price movements.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SUGP is trending due to its low float and comparisons to other Hong Kong stocks like $SMX and $OCG that have seen significant gains, with traders anticipating a potential short squeeze and a run to higher price levels. Community members are closely watching key resistance levels, viewing breaks above them as bullish signals. The stock's setup, including a potential golden cross, is fueling speculation about a substantial move.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors weigh the potential impact of its upcoming move to the Nasdaq exchange and speculate on new OEM partnerships. The community is focused on the progress of the Eagle Line facility in early 2026 and anticipates further developments on commercialization and scaling, with bullish investors confident in the company's long-term potential in the EV battery market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>AXIL’s hearing products will hit over 3,700 Walmart stores, marking its largest single retail placement ever.&nbsp;</li><li>AXIL already has partnerships with Costco’s 300-plus retail and online stores.&nbsp;</li><li>Shares of AXIL are up over 30% in the last year.&nbsp;</li></ul>AXIL Brands, Inc. (AXIL) shares soared in Thursday’s premarket trade after the company announced a national retail distribution agreement with Walmart, which will bring its hearing protection and enhancement products to a massive new audience.The company said that under the agreement, AXIL's products, including its new AXIL® X30 LT earplugs, would be available in over 3,700 Walmart stores.&nbsp;According to the statement, the Walmart rollout represents the firm’s largest single retail placement to date.Shares of AXIL soared over 150% on the announcement.&nbsp;<h2 class="st-heading-2">New Horizons</h2>AXIL’s debut at Walmart is slated for February 2026, with the launch of a new product, the AXIL® X30 LT in-ear hearing protection plugs, available in retail outlets.In September this year, AXIL&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://goaxil.com/blogs/press-releases/axil-brands-launches-nationwide-at-costco-with-axil-xcor-se-advanced-hearing-protection-and-enhancement-earbuds">partnered with Costco</a> to take its earbuds to over 300 stores in the U.S. and eventually expanded to offer them on Costco’s online platform as well.&nbsp;Between Walmart and Costco placements, Axil’s expansion gives it access to millions of American consumers. In the latest statement, the company said that these partnerships position it for faster growth and greater brand visibility starting in 2026.“This partnership is a testament to the performance, value, and consumer demand for our products and will make our best-in-class hearing protection and enhancement technology available to millions of consumers who shop at Walmart every day,” Jeff Toghraie, Chairman and CEO at AXIL Brands, said.&nbsp;In October, <a href="https://stocktwits.com/symbol/AXIL">AXIL</a> announced its first-quarter (Q1) 2026 results, reporting a 17.2% increase in quarterly sales and an improvement in operating income of $0.4 million, compared to an operating loss in the same period last year.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AXIL jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped to ‘extremely high’ levels at the time of writing.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_11_at_5_03_15_PM_png_87987f7875.webp" alt="Screenshot 2025-12-11 at 5.03.15 PM.png">One user stressed their bullish outlook on the stock.&nbsp;<stembedurl>https://stocktwits.com/nader_1/message/638834530</stembedurl>Shares of AXIL are up over 30% in the last year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

The exterior of a Walmart store in Hollywood, Florida. (Photo by Joe Raedle/Getty Images)

 AXIL Stock Just Rocketed Over 150% Today — What’s The Walmart Angle? 

AXIL Brands announced a partnership with Walmart that would bring its products to the stores of America’s largest retailer.

Equity

<ul class="summary-bullets"><li>SENTI-202, the immune cell therapy cancer treatment, received a Regenerative Medicine Advanced Therapy (RMAT) designation that would make it eligible for quicker reviews.</li><li>This is the second FDA designation for the treatment this year.&nbsp;</li><li>On Stocktwits, retail sentiment for the stock rose to ‘extremely bullish’ territory while message volume jumped to ‘extremely high’ levels at the time of writing. &nbsp;</li></ul>Shares of Senti Biosciences, Inc. (SNTI) surged over 20% on Tuesday’s premarket trading after the company announced positive news around its cancer treatment.&nbsp;The clinical-stage biotech company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.sentibio.com/news-releases/news-release-details/senti-bio-announces-updated-senti-202-clinical-data-ongoing">announced</a> in a press release that the U.S. Food and Drug Administration (FDA) gave SENTI-202, an immune cell therapy cancer treatment, a Regenerative Medicine Advanced Therapy (RMAT) designation.&nbsp;<h2 class="st-heading-2">What Does This Mean?</h2>The RMAT designation from the FDA for the company’s cancer treatment indicates an expedited development and review, providing benefits similar to the FDA’s Breakthrough Therapy and the Fast Track programs such as higher interactions with the Agency through the development process as well as eligibility for quicker and even priority reviews.“This significant FDA designation validates both the tremendous need for better treatments for R/R AML and the promise of SENTI-202 to transform the therapeutic landscape for this notoriously aggressive cancer,” said Timothy Lu, Co-Founder and CEO of Senti Biosciences, in the press release. “We are incredibly pleased with the exciting clinical progress we recently shared at the ASH conference on SENTI-202.”Data from its ongoing trial showed a 50% overall response rate and 42% complete remission at the recommended Phase 2 dose, the company revealed. Earlier this year, the U.S. FDA granted the treatment Orphan Drug Designation.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/SNTI">SNTI</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1284/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_09_at_7_13_22_PM_png_c037e194c0.webp" alt="On Stocktwits, retail sentiment around&nbsp;SNTI jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels." width="1284" height="149"></figure>One user on the platform predicted that STNI’s share price could go up to $5. The stock was trading around $2.85 at the time of writing.&nbsp;<stembedurl>https://stocktwits.com/Stratsys/message/638587949</stembedurl>Shares of SNTI have fallen over 37% year to date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a medicine pill is seen in a hand dressed in a medical glove with the U.S. FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) 

SNTI Shares Surge Over 20% In Pre-Market Trade After FDA RMAT Designation For Cancer Treatment

Senti Biopharma shares rallied in premarket trading on Tuesday after its cancer treatment received a positive designation from the U.S. FDA.

SNTI Shares Surge Over 20% In Pre-Market Trade After FDA RMAT Designation For Cancer Treatment 

<ul class="summary-bullets"><li>Roth Capital sees potential FDA clearance for the software.</li><li>The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, the analyst said.&nbsp;</li><li>HeartBeam is now evaluating launching its 3D ECG system, which received FDA clearance in December 2024.</li></ul>Shares of HeartBeam, Inc. (BEAT) slumped 58% on Friday afternoon after the company said that the U.S. Food and Drug Administration refused clearance for its 12-Lead Electrocardiogram (ECG) Synthesis Software for arrhythmia assessment.The medical technology company said that it received a ‘not substantially equivalent’ letter from the FDA. A "Not Substantially Equivalent" (NSE) letter is an official notification from the FDA stating that a new medical device is not considered substantially equivalent to a legally marketed predicate device.The company said that it will be working with the agency to get to a resolution and expressed confidence in its clinical data. Earlier this month, HeartBeam had touted FDA clearance for the software as a major inflection point for the company.The company is now evaluating launching its 3D ECG system which received FDA clearance in December 2024.<h2 class="st-heading-2">Analyst Takeaway</h2>Roth Capital, however, sees potential FDA clearance for the software. The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, it said.While resolving the pathway for the 12-lead ECG synthesis software, management may decide to roll out the foundational 3D ECG system to concierge medical practices, preventive cardiology clinics, and hospital-at-home programs, the analyst said, as per The Fly.The analyst kept a ‘Buy’ rating on HeartBeam with a $4 price target. The price target represents a potential upside of over 138% from the stock’s closing price on Thursday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BEAT">BEAT stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user echoed Roth Capital’s opinion and said that the stock would beat $5 on FDA approval.<stembedurl>https://stocktwits.com/jamestocklover/message/637108009</stembedurl>Another noted that an NSE letter is not the end.<stembedurl>https://stocktwits.com/Rolltide2020/message/637103348</stembedurl>BEAT stock is down by 70% this year and by about 75% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/will-scot-stock-surges-after-baird-upgrade-analyst-calls-q3-a-watershed-quarter/cLPMv4RREfb">WillScot Stock Surges After Baird Upgrade – Analyst Calls Q3 A ‘Watershed Quarter’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

HeartBeam Stock Slumps After FDA Refuses Clearance For ECG Software

The company said it will work with the agency to reach a resolution and expressed confidence in its clinical data.

<ul><li>According to Telomir, more than 60,000 new cases of Leukemia are diagnosed each year in the U.S.</li><li>Leukemia cells rely heavily on iron as a fuel source, and Telomir-1 in previous research demonstrated the ability to reduce intracellular iron levels.&nbsp;</li><li>The new findings expand on the experimental drug’s previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models.</li></ul>Telomir Pharmaceuticals, Inc. (TELO) said on Friday that its investigational compound Telomir-1 killed aggressive human leukemia (HL60) cells in an in-vitro study.HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.Leukemia is a cancer of the blood and bone marrow defined by the uncontrolled growth of abnormal white blood cells.<a href="https://stocktwits.com/symbol/TELO">TELO shares</a> rose 8% at the time of writing.<h2 class="st-heading-2">New Findings</h2>According to Telomir, more than 60,000 new cases of Leukemia are diagnosed each year in the U.S. Leukemia cells rely heavily on iron as a fuel source, and Telomir-1 in previous research demonstrated the ability to reduce intracellular iron levels."The potency observed in HL60 leukemia cells is consistent with the broader biological patterns we have seen throughout Telomir's research…These findings support our scientific framework for evaluating Telomir-1 and inform the ongoing advancement of our overall oncology research program," the company’s chief scientific advisor, Itzchak Angel,<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://telomirpharma.com/#"> said</a>.The new findings expand on the experimental drug’s previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. The compound is the company’s lead candidate.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TELO jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume levels rose from ‘extremely low’ to ‘high’ levels.TELO stock is down 66% this year and by 69% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/google-ai-infra-chief-must-double-ai-compute-twice-a-year/cLPMFWiREOK">Google AI Infra Chief Says It Must Double AI Compute Twice A Year To Meet Demand: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Telomir Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death 

HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.

<ul class="summary-bullets"><li>Matt Kinsella said that computing is not the only product coming from quantum technologies.</li><li>There's a&nbsp;wide range of other products, including quantum sensors, quantum clocks, RF antennas, gravimeters, and&nbsp;different types of inertial sensing equipment.</li><li>Citing McKinsey’s research, the executive said Infleqtion’s total addressable market (TAM) is about $160 billion.</li></ul>Quantum computing company Infleqtion is set to go public via a Special Purpose Acquisition Company (SPAC) deal with Churchill Capital Corp. (CCCX), a blank-check company founded by ex-Citi executive Michael Klein. The ongoing government shutdown may have pushed back the going-public timeline slightly.&nbsp;Still, it hasn’t dampened Infleqtion CEO Matt Kinsella's optimism&nbsp;about&nbsp;what the future holds out for the company.Since the SPAC deal was announced, <a href="https://stocktwits.com/symbol/CCCX">Churchill Capital stock</a> has gained about 60%.Stockwits sat down with Kinsella, a former venture capitalist and a breakthrough technology evangelist, for a freewheeling chat about Inflqeqtion and its way forward:Here are excerpts from the interview:<h2 class="st-heading-2">Quantum Tech Is Much More Than Computing</h2>Kinsella attributed the skepticism toward the quantum computing industry to&nbsp;the pushed-out timelines. “For the last 20 years, it's always kind of been, oh, in five years we'll have quantum computing. It's always been this kind of rolling five years, and when you get there, it's five years from now we'll have it, and then five years from now you'll have it,” he said.The skepticism, according to the executive, stems from a bucket of misconceptions — that computing is the only product&nbsp;emerging from&nbsp;quantum technologies. “There's a whole umbrella of other types of products, such as quantum sensors, where quantum is already developing products that are truly orders of magnitude better than classical standards.” He also mentioned products such as quantum clocks, RF antennas, gravimeters, and other types of inertial sensing equipment.<h2 class="st-heading-2">Quantum Space In An Excited State</h2>Quantum computing stocks began the year on a slow note as they digested the torrid gains made in 2024, most of which occurred late in the year. These stocks also moved in tandem with the broader market when it declined sharply in early April, following President Donald Trump's announcement of punitive tariffs.&nbsp;Rumors that the Trump administration was eyeing stakes in quantum companies provided a solid boost to these stocks in October. D-Wave Quantum is among the best-performing publicly listed quantum companies this year,&nbsp;with gains exceeding 175%.<img src="https://news.stocktwits-cdn.com/QC_Stocks_Price_Gains_png_8e6c1e3da2.webp" alt="QC Stocks Price Gains.png">Source: KoyfinCitron Research touted in early October that Infleqtion is a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-spac-churchill-capital-s-stock-is-jumping-premarket-today/ch6EfqhR3Ln">far better quantum play&nbsp;</a>than Rigetti.Big Tech companies have also made significant inroads in quantum computing, with Alphabet announcing its Willow quantum chip late last year. Last month, it unveiled a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-tips-hat-to-sundar-pichai-for-google-s-latest-quantum-leap/cLG49mqR3Ag">breakthrough quantum algorithm,</a> dubbed “Quantum Echoes,”&nbsp;which CEO Sundar Pichai&nbsp;claims is 13,000 times faster than the best classical algorithm on one of the world's fastest supercomputers.&nbsp;That earned adulation even from Tesla CEO Elon Musk, who replied, “Looks like quantum computing is becoming relevant.”&nbsp;On Wednesday, IBM unveiled IBM Quantum Nighthawk, its most advanced quantum processor yet. As the industry makes slow and steady progress toward large-scale commercial adoption, Infleqtion finds itself in the sweet spot, positioning itself as a provider of a broad array of quantum products.<h2 class="st-heading-2">The Qubit Conundrum</h2>Kinsella said another misconception is a lack of understanding of the concept of logical qubits.&nbsp;A qubit&nbsp;is the basic unit of information in quantum computing, analogous to a bit in classical computing.He said Infleqtion holds the record for commercial qubits at 1600. “These are physical qubits, but what really matters in quantum computing are logical qubits. And logical qubits are error-corrected physical qubits.”“And it's generally thought that at 100 logical qubits, we will start to be able to do things with quantum computers that classical computers can't do.”Kinsella conceded that in terms of quantum computing, “we are not yet there.” While companies have different roadmaps for their logical qubits, Infleqtion plans to have 100 logical qubits by 2028. “So I think that's a reasonable line in the sand to say we'll start to do things that are commercially useful with quantum computers.”<h2 class="st-heading-2">Trump’s Quantum Thrust</h2>To a question about the Trump administration’s rumored interest in taking stakes in quantum computing companies, just as it invested in rare earth companies, Kinsella said such a move is possible. “I think it's the mentality of this administration to have taxpayers benefit from work that the government does with various deep tech companies.”Kinsella said the U.S. government is Infleqtion’s biggest customer and the company is constantly in talks with the government. “The topic of equity is brought up from time to time, and so I think, you know, we will continue to do a lot of business with the U.S. government, and those conversations will play out as they play out.”<h2 class="st-heading-2">China Competition</h2>It’s a race with China, just like it is in other areas. Kinsella said China is investing significantly more dollars in quantum than the U.S. has historically, but the U.S., along with its allies, invests more than China does. “But importantly, I think the U.S. is doing what it does often, and that's relying on its private capital markets to fund the innovation.”<h2 class="st-heading-2">Biggest Customer</h2>Kinsella said government accounts for more than 50% of Infleqtion’s revenue, with the Department of Defense (DoD) and government-run energy grids included in this category. The&nbsp;company also sells its clocks to non-governmental customers and academic institutions.Citing McKinsey’s research, the executive stated that Infleqtion’s total addressable market (TAM) is approximately $160 billion, comprising $30 billion in quantum sensing revenue and $130 billion in quantum computing revenue.&nbsp;<h2 class="st-heading-2">Consolidation In the Offing?</h2>While hinting that quantum computing is not a zero-sum game, Kinsella sees some degree of consolidation. “I think you'll probably end up with a handful of very large, very important quantum companies over the course of the next five to 10 years.”“One of the reasons why&nbsp;Infleqtion is going public is because I think we will be one of those consolidators, and we'll be one of those important companies. I think we have a head start now and an advantage, and we want to compound that advantage going forward.”<h2 class="st-heading-2">Government Shutdown Throws A Wrench</h2>Kinsella said Infleqtion was shooting for the end-of-the-year listing timeframe. “I hadn't really factored in the government shutdown into my calculations, and so I think it'll probably be in Q1, assuming the government gets reopened. Is it January or March? I don't know at this point.” The executive noted that the company has filed the S4 report confidentially with the SEC.<h2 class="st-heading-2">Message For Retail Investors</h2>“I personally believe quantum is going to be a very important technological shift for humanity over the course of the next decade. And I think it's great that the retail investing community is going to have more options to be able to participate in that over time,”&nbsp;Kinsella said, urging retail investors to do their due diligence. “But I think it's great that there will be the opportunity to invest in, you know, now another quantum company like Infleqtion.”“If you want to have exposure to the broad spectrum of opportunities that quantum can provide across both sensing and computing, Infleqtion is a very good way to represent that broader quantum bet.”Infleqtion will be the only publicly traded neutral-atom quantum, he said.&nbsp;That means it’s a company&nbsp;that develops quantum computers using neutral atoms, which&nbsp;lack an electrical charge. These companies use lasers to trap and manipulate these neutral atoms, arranging them into precise configurations to act as qubits for complex calculations.Kinsella thinks “neutral atoms are going to be the ones that win in quantum computing and therefore, we would be the way to express that.”For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/intel-hit-by-ai-brain-drain-as-top-execs-depart-for-rivals/cLPdQ7DRE2w">&nbsp;Intel Hit By AI Brain Drain As Top Execs Depart For Rivals: Sachin Katti Joins OpenAI After Saurabh Kulkarni's Jump To AMD</a>

 Citron Research touted in early October that Infleqtion is a far better quantum play than Rigetti.

EXCLUSIVE: Quantum Stocks Are Still Hot — And Infleqtion's CEO Sees Industry Consolidation, $160B Opportunity As It Heads For SPAC Listing

Quantum computing company Infleqtion is set to go public via a Special Purpose Acquisition Company (SPAC) deal with Churchill Capital Corp. 

Quantum Stocks Are Still Hot — And Infleqtion's CEO Sees Industry Consolidation, $160B Opportunity As It Heads For SPAC Listing

Matt Kinsella says quantum technology will be a major technological shift for humanity over the next decade.


<ul class="summary-bullets"><li>CEO Kevin McAleenan said, with the Ask Sage deal, BigBear is creating a secure, integrated AI platform that connects software, data, and mission services in one place.</li><li>The deal is expected to close in either the fourth quarter or the first quarter of next year.</li><li>Despite the ongoing government shutdown, the company reaffirmed its 2025 revenue guidance.</li></ul>Big Bear.ai Holdings, Inc. (BBAI) stock jumped over 12% in Monday’s extended session after the company reported a third-quarter beat and announced an M&amp;A deal, buoying retail sentiment.<a href="https://stocktwits.com/symbol/BBAI">BigBear stock</a> has been on a volatile ride this year en route to its 28% year-to-date gains.&nbsp;<h2 class="st-heading-2">BigBear’s Doubled Down AI Bet</h2>The McLean, Virginia-based artificial intelligence (AI)-powered decision intelligence solutions company said it has signed an agreement to buy Ask Sage for $250 million. Ask Sage is a generative AI (GenAI) platform designed for the secure distribution of AI models and agentic AI capabilities, primarily for defense and national security agencies and other highly regulated sectors.Big Bear noted that Sage already supports more than 100,000 users on 16,000 government teams and across hundreds of commercial companies. Ask Sage is expected to deliver annual recurring revenue (ARR) of approximately $25 million in 2025, nearly six times the amount it recorded in 2024.&nbsp;CEO Kevin McAleenan said, “By integrating Ask Sage with BigBear.ai, we are creating what the market has been asking for: a secure, integrated AI platform that connects software, data, and mission services in one place.” The deal is expected to close in either the fourth quarter of 2025 or the first quarter of 2026.<h2 class="st-heading-2">BigBear’s Q3 Earnings Snapshot</h2>The net loss per share for the fiscal year 2025 fourth quarter narrowed to $0.03 from $0.06 a year ago, and revenue fell 20% year over year (YoY) to $33.1 million. The results, however, exceeded the Fiscal.ai-compiled consensus estimates for a loss of $0.07 and revenue of $31.82 million.The company blamed the YoY revenue drop on lower volume in certain Army programs, and said the narrower net loss is due to non-cash changes in the fair value of the convertible 2029 notes and warrants.&nbsp;Gross margin contracted 350 basis points YoY due to the absence of some high-margin programs that benefited the year-ago quarter.BigBear ended the quarter with a backlog of $376 million.<h2 class="st-heading-2">BigBear’s Outlook</h2>Despite the ongoing government shutdown, the company reaffirmed its 2025 revenue guidance of $125 million to $140 million, which aligns with the consensus estimate of $133.53 million.<h2 class="st-heading-2">What BigBear Retail Feels About Stock After Q3 Print</h2>On Stocktwits, retail sentiment toward the stock shifted to ‘bullish’ as of early Tuesday, from ‘bearish’ a day ago. The 24-hour message volume leading up to late&nbsp; Monday surged up by about 1,500%.<figure class="image"><img style="aspect-ratio:677/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_11_11_at_12_27_52_AM_png_f6bac86ee7.webp" alt="Screenshot 2025-11-11 at 12.27.52 AM.png" width="677" height="58"><figcaption>BBAI sentiment and message volume as of 2:25 a.m. ET, Nov. 11 | source: Stocktwits</figcaption></figure>A bullish watcher said there is a good chance the stock will open above $7 on Tuesday.<stembedurl>https://stocktwits.com/MyEfund/message/635695260</stembedurl>Another user expressed comfort in&nbsp;holding the stock. “I don’t feel as bad holding this stock anymore after today’s earnings call.”<stembedurl>https://stocktwits.com/DARK_SCROOGIE/message/635690861</stembedurl>The average analysts' price target for BigBear stock is $5.83, according to Koyfin, implying roughly 2% upside from Monday's closing price.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/intel-hit-by-ai-brain-drain-as-top-execs-depart-for-rivals/cLPdQ7DRE2w">Intel Hit By AI Brain Drain As Top Execs Depart For Rivals: Sachin Katti Joins OpenAI After Saurabh Kulkarni's Jump To AMD</a>

The logo of BigBear.ai Holdings, Inc. displayed on a smartphone screen, with the company's latest stock market chart visible in the background on April 26, 2025, in Chongqing, China. (Photo illustration credit: Cheng Xin/Getty Images)

BigBear Stock Surges Over 12% After-Hours On $250M Ask Sage Deal, Q3 Beat — Retail Impressed With Results

BigBear announced a strategic acquisition of a GenAI platform, which is growing revenue at a scorching pace.

BigBear Stock Surges Over 12% After-Hours On $250M Ask Sage Deal, Q3 Beat

<ul class="summary-bullets"><li>According to Fiscal.ai-compiled consensus, BigBear is expected to report a loss per share of $0.07 and revenue of $31.82 million.</li><li>During the quarter, the company announced several deals, including one that aims to deploy advanced AI and orchestration technologies in support of the U.S. Navy.</li><li>BigBear stock is up about 17.7% YTD.</li></ul>Big Bear.ai Holdings, Inc. (BBAI) stock rallied nearly 4% in premarket trade ahead of the company’s quarterly earnings report, due after the market closes on Monday. The artificial intelligence (AI)-powered decision intelligence solutions firm has attracted attention from retail traders, even as analysts forecast a wider loss and lower revenue compared to last year.For the year-to-date period,&nbsp;<a href="https://stocktwits.com/symbol/BBAI">BigBear stock</a> has gained about 17.7%, underperforming the broader market and the tech sector.<h2 class="st-heading-2">Retail Excited About BigBear’s Q3</h2>When retail users of the Stocktwits platform were asked which earnings report they were most excited for the week of Nov.10, a majority picked BigBear, reflecting interest in the stock. An ongoing poll that has received responses from 11,200 users so far has shown that 30% are excited about BigBear’s earnings. AST SpaceMobile (ASTS), Nebius N.V. (NBIS) and Rocket Lab (RKLB) were mentioned by 25%, 23% and 22% of the respondents, respectively.<a href="https://stocktwits.com/StocktwitsPolls/message/635353734"><img src="https://news.stocktwits-cdn.com/Screenshot_2025_11_10_at_4_37_04_AM_png_a62853f334.webp" alt="Screenshot 2025-11-10 at 4.37.04 AM.png"></a>A Stocktwits user hoped the stock would gain enough momentum to hit double digits before Christmas, based on the view that BigBear's earnings report would not be too bad. Another user stated that the stock is poised to take off and will continue rallying until the end of the year. They set their sights on $12.<stembedurl>https://stocktwits.com/Paul243/message/635557229</stembedurl><stembedurl>https://stocktwits.com/Ohad12/message/635559688</stembedurl>A third user said he would continue to stack the stock.<stembedurl>https://stocktwits.com/marzo34/message/635554283</stembedurl><h2 class="st-heading-2">What Analysts Expect From BigBear’s Q3 Print</h2>According to Fiscal.ai-compiled consensus, BigBear is expected to report a loss per share of $0.07 and revenue of $31.82 million. This compares to the year-ago’s loss per share of $0.05 and revenue of $41.51 million.During the quarter, the company announced several deals, including one that aims to deploy advanced AI and orchestration technologies in support of the U.S. Naval Forces Southern Command. The company also announced a strategic partnership with Tsecond to deliver AI-enabled edge infrastructure for mission-critical operations.The average analysts’ price target for BigBear stock is $5.83, according to Koyfin, implying roughly 2.70% potential upside.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-rumble-stock-is-soaring-nearly-16-in-premarket/cLPcX3hREcH">Why Rumble Stock Is Soaring Nearly 16% In Premarket</a>

In this photo illustration, a person holds a smartphone displaying the logo of BigBear.ai Holdings, Inc. (NYSE: BBAI), on August 8, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

BigBear Retail’s Top Earnings Pick Of The Week Ahead: Stock Gains Nearly 4% Premarket Ahead Of Q3 

BigBear retail is buzzing about the stock taking off and rallying through the year-end.

<ul class="summary-bullets"><li>Strive, following its merger with Asset Entities in mid-September, announced plans to become a Bitcoin holding company.</li><li>Bitcoin topped the $116K earlier in the Asian session, before giving back some of the gains.</li><li>The optimism toward cryptocurrencies stemmed from a raft of catalysts, including the brightening prospects of a U.S.-China deal.</li></ul>Strive Asset Management, LLC (ASST) stock climbed sharply in Monday’s early premarket session, signaling that it may rise for a third consecutive session.On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/ASST">Strive stock</a> remained ‘extremely bullish’ as of early Monday, and the message volume jumped to ‘extremely high’ levels.<h2 class="st-heading-2">Strive’s Bitcoin-Inspired Rally?</h2>Nasdaq-listed Asset Entities, a marketing company, closed its merger with asset management company Strive in mid-September, retaining the Strive name and ‘ASST’ ticker. The company, co-founded by Vivek Ramaswami, announced plans to become a Bitcoin (BTC) holding and marketing company.ASST’s premarket gains on Monday could be traced to strong gains in Bitcoin (BTC), which topped the $116K earlier in the Asian session,&nbsp;before giving back some of the gains. The optimism toward crypto stemmed from a raft of catalysts, including the brightening prospects of a U.S.-China deal following productive high-level talks between the two countries in Malaysia over the weekend.Hopes of a rate cut from the Federal Reserve’s rate-setting committee, when it meets for a two-day meeting that kicks off on Tuesday, also lent support to cryptocurrencies.<h2 class="st-heading-2">What Retail’s Feeling About Strive Stock</h2>Retail’s interest in Strive’s stock has been on the rise, with the one-year follower count rising 675% and the message volume over the past seven days leading up to late Sunday was up over 900%.A bullish watcher lauded the company for the bold move to merge and become the first public Bitcoin treasury company, backed by a massive $750 million funding plan. “Big vision, big potential!” they said.<stembedurl>https://stocktwits.com/StockGuru95/message/633790891</stembedurl>Another user expected algorithmic buying on Monday, just like last Friday, when it ripped before remaining stuck for a long time.<stembedurl>https://stocktwits.com/Ammylovlov/message/633790840</stembedurl>Since its mid-September listing, the stock has lost about 82%. In premarket, the stock climbed over 26% on top of Friday’s 27%+ rally.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-avidity-biosciences-stock-is-jumping-over-43-in-premarket-today/cLG0dICR3Ma">Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today</a>

Why Strive Stock Is Ripping Higher In Premarket Today

Strive Asset Management, LLC (ASST) stock climbed sharply in Monday’s early premarket session, signaling that it may rise for a third consecutive session.

Why Strive (ASST) Stock Is Ripping Higher In Premarket Today

<ul class="summary-bullets"><li>Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.</li><li>The deal is expected to close in the first half of 2026.</li><li>Retail sentiment toward Avidity Biosciences stock flipped to ‘extremely bullish’ by early Monday from ‘bearish’ a day ago.</li></ul>Avidity Biosciences, Inc. (RNA) shares&nbsp;soared over 43% in Monday’s early premarket session after the mid-cap biopharma focusing on developing RNA therapeutics called antibody oligonucleotide conjugates (AOC), announced a deal to be bought by Swiss pharma giant Novartis (NVS).<a href="https://stocktwits.com/symbol/RNA">Avidity Biosciences</a> stock has gained more than 60% this year.<h2 class="st-heading-2">The Novartis Deal Terms</h2>In a statement released on Sunday, Novartis said it would acquire San Diego-based Avidity Biosciences following the separation of the latter’s early-stage precision cardiology programs. The deal, approved by the boards of both companies, is valued at $72 per share in cash. This represented a 46% premium over RNA stock’s closing price of $49.15 on Friday.The total transaction value is $12 billion on a fully diluted basis. Avidity Biosciences currently boasts a market capitalization of $7.17 billion.Vas Narasimhan, CEO of Novartis, said, “Avidity’s pioneering AOC platform for RNA therapeutics ​and its late-stage assets bolster our commitment to delivering innovative, targeted, and potentially first-in-class medicines to treat devastating, progressive neuromuscular diseases.”Before the merger's closing, Avidity will transfer its early-stage precision cardiology programs and collaborations to SpinCo, a wholly owned subsidiary of Avidity. Holders of Avidity common stock will receive a distribution of one share of SpinCo for every ten shares of Avidity they hold and/or a pro rata cash distribution of the proceeds received by Avidity before the closing if certain SpinCo assets are, or SpinCo itself is, sold to a third party.The deal is expected to close in the first half of 2026, subject to the completion of a spin-off or the sale of SpinCo and other customary closing conditions, including the receipt of regulatory approvals and the approval of Avidity stockholders.Novartis said the proposed acquisition raises the expected 2024-2029 sales growth from 5% to 6% on a compounded annual growth rate (CAGR) basis, representing a significant opportunity to deliver substantial shareholder returns over time.<h2 class="st-heading-2">What Retail’s Saying About The Buyout Deal</h2>Retail sentiment toward Avidity Biosciences stock flipped to ‘extremely bullish’ by early Monday from ‘bearish’ a day ago. The message volume on the stream also improved to ‘extremely high.’&nbsp; Retail chatter spiked 6,100% over the 24 hours leading up to late Sunday.<figure class="image"><img style="aspect-ratio:620/56;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_27_at_6_02_00_AM_png_9d47ea362a.webp" alt="Screenshot 2025-10-27 at 6.02.00 AM.png" width="620" height="56"><figcaption>RNA sentiment and message volume as of 6 a.m. ET, Oct. 27 | source: Stocktwits</figcaption></figure>A bullish user noted that RNA traded at $5 two years ago and congratulated the believers.<stembedurl>https://stocktwits.com/Cutlass/message/633766787</stembedurl>Another user said they would cash out on Monday.<stembedurl>https://stocktwits.com/ure300/message/633760283</stembedurl>Earlier this month, Avidity Biosciences said it has completed a positive pre-Biologic License Application (BLA) meeting with the FDA regarding its delpacibart zotadirsen, an investigational drug being evaluated as a potential treatment for people living with Duchenne muscular dystrophy (DMD) who have gene mutations amenable to exon 44 skipping.&nbsp;The timing for the BLA submission was pushed back to the first quarter of 2026 from the previous guidance of year-end 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palantir-rises-premarket-today-as-stock-closes-in-on-200-psychological-threshold/cLG0TBNR3Md">Palantir Rises Premarket Today As Stock Closes In On $200 Psychological Threshold: What’s Driving The Gains?</a>

Researcher performing microbiology separator for PCR diagnosis test in pathology laboratory. 

Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today

Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.

Why Avidity Biosciences Stock Is Jumping Over 40% In Premarket Today

&nbsp;<ul class="summary-bullets"><li>In an amended&nbsp;regulatory filing, AiRWA confirmed a stake built by director Michael Anthony Belfiore.</li><li>According to the filing, he now holds a 22.1% stake in AiRWA.</li><li>Retail expects “FOMO” fear will kick in once the stock reaches $0.50.</li></ul>Nano-cap AiRWA, Inc.’s (YYAI) stock fell for two consecutive sessions this week, but rebounded by nearly 32% in Tuesday’s after-hours session, accompanied by substantial volume,&nbsp;following a filing by the company confirming an insider’s stake build.<a href="https://stocktwits.com/symbol/YYAI">AiRWA stock</a>, which has traded in a 52-week range of $0.0670 to $6.33, has elicited a strong bullish reaction from retail traders.<h2 class="st-heading-2">Insider Accumulates AiRWA Stock</h2>In an amended Schedule 13D filing with the SEC, AiRWA confirmed the stake build by director Michael Anthony Belfiore, which the company disclosed earlier this month. A Schedule 13D is filed by a person who acquires more than 5% of a voting class of a company’s stock, and who does not otherwise qualify to file a short-form report on Schedule 13G. It has to be filed within 10 days of the purchase of more than 5% stake.&nbsp;The company filed a Form 4 with the SEC on Oct. 15, stating that Belfiore purchased 3.21 million AiWA stock shares between Oct. 8 and Oct. 10, valued at $1.03 million. According to the 13D filing, Belfiore now holds a 22.1% stake in AiRWA.AiRWA, formerly Connexa Sports Technologies, rebranded itself to the present name on Oct. 7, underlining its thrust into the Web3 space and blockchain technology. In late August, the company, which was then called Connex Sports, struck a $500 million agreement with Singapore-based JuCoin to establish aiRWA, a next-generation digital asset platform jointly.&nbsp;According to the companies, the venture will focus on real-world asset (RWA) tokenization aimed at bringing traditional investments such as real estate, government bonds, and fine arts into a digital format. As part of the deal, JuCoin committed a $100 million investment in AiRWA, including about $30 million of Solana (SOL) tokens.<h2 class="st-heading-2">How Retail Feels About AiRWA Stock</h2>On Stocktwits, retail sentiment toward AiRWA stock shifted to ‘extremely bullish’ from the ‘bullish’ mood seen a day ago. The message volume remained at ‘extremely high’ levels. Retail chatter spiked nearly 3,500% in the 24 hours leading up to late Tuesday.<figure class="image"><img style="aspect-ratio:621/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_22_at_1_55_49_AM_png_5452a973dc.webp" alt="Screenshot 2025-10-22 at 1.55.49 AM.png" width="621" height="57"><figcaption>YYAI sentiment and message volume as of 1:55 a.m. ET, Oct. 22 | source: Stocktwits</figcaption></figure>One bullish user said “FOMO” fear will kick in once the stock reaches $0.50, and predicted a move to $1. Another user noted that retail traders’ support could push the price past the level.<stembedurl>https://stocktwits.com/ineedmore/message/633174405</stembedurl><stembedurl>https://stocktwits.com/ineedmore/message/633172951</stembedurl>AirWA stock, which fell 19.18% on Tuesday to $0.0809, was seen jumping 44% in overnight trading, according to Yahoo Finance.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-pega-stock-surge-over-13-in-after-hours-trading/cLGPxWaR3pl">Why Did PEGA Stock Surge Over 13% In After-Hours Trading?</a>

YYAI Stock Rockets After Insider Buying Reveal: Retail Trader FOMO Builds

In an amended regulatory filing, AiRWA confirmed a stake built by director Michael Anthony Belfiore.

IWC
iShares Micro-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWC News

IWCiShares Micro-Cap ETF